In Part 1 of our Series on how the pharma landscape is being reshaped - from the inside out, we have Eyes On how cost discipline, manufacturing shifts, and portfolio resets are reshaping large pharma.

Last week we had Eyes On more M&A counter offers + the success of M&A as Kura Oncology's Komzifti gets approved in the US (partner Kyowa Kirin). What caught you eye in BioPharma News lately?

MFN — once a policy abstraction — is now reshaping corporate strategy, pricing frameworks, and commercialization models.

The newest pharmaceutical behemoths to reach MFN pricing agreements with the White House are Eli Lilly and Novo Nordisk, who have agreed to sell their weight-loss medications to Americans at reduced costs.

This week, following up on our recent post about Merck, we had Eyes On their recent bid for Cidara Therapeutics. This time, the acquisition is made to diversify their portfolio further, adding an antiviral asset for Influenza prophylaxis. This asset, CD 388, could provide a new class of prophylaxis, outside of the current vaccines area.

At PharmaTell we keep Eyes on Strategic moves within the market. This week we're diving into Merck & Co's plans for the future. With the upcoming patent expiry for Keytruda, they are planning to bolster their pipeline with new products and indications via internal development and M&A.